Stockreport

NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study [Yahoo! Finance]

NovaBridge Biosciences - American Depositary Shares  (NBP) 
PDF NovaBridge Biosciences VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a [Read more]